Earnings Forecast Today’s Market: J.C. Penney, Microsoft, Merck, Apple, General Electric, and America Movil SAB de CV
HONG KONG, March 13, 2013 /PRNewswire/ — EarningForecast.com has issued consensus earnings forecast reports for the following companies: J.C. Penney (NYSE:JCP), Microsoft (NASDAQ:MSFT), Merck (NYSE:MRK), Apple (NASDAQ:AAPL), General Electric (NYSE:GE), and America Movil SAB de CV (NYSE:AMX).
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
J.C. Penney Company, Inc. (NYSE:JCP): By the end of trading session, J.C. Penney Company, Inc. (NYSE:JCP) shares rose 3.99% (or US$0.60) to US$15.65 with more than 35.91 million shares traded, compared to its average volume of 14.46 million shares. J.C. Penney’s spokesman denied company CEO, Ron Johnson, is resigning. Observing comprehensive analysis of J.C. Penney could help investors avoid big lost in investment. Check JCP earnings forecast report below.
Read Full Report: http://www.earningforecast.com/PR/031313A/JCP/JCPenney.pdf
Microsoft Corporation (NASDAQ:MSFT): Microsoft Corporation (NASDAQ:MSFT) shares began the trading session with a price of US$27.84. When day-trade ended, the stock finally rose 0.14% to US$27.91. The stock traded 39.26 million shares in the last trading session, compared to its daily average of 41.65 million shares. According to the Form 6-K that Nokia filed with SEC, it warned its shareholders that Microsoft will produce competing Windows Phone based products. Investors may want to find out where Microsoft will go from here. Observe comprehensive MSFT earnings forecast report here.
Read Full Report: http://www.earningforecast.com/PR/031313A/MSFT/Microsoft.pdf
Merck & Co., Inc. (NYSE:MRK): The share of Merck & Co., Inc. (NYSE:MRK) began the trading session with a price of US$45.42. When day-trade ended, the stock price soared 3.16% to US$45.04. The stock traded 56.01 million shares in the last trading session, higher than its daily average of 17.42 million shares. The company shareholders received a good news from an independent safety panel that their Vytorin can be continued its clinical trial evaluating the effectiveness and safety. Vytorin can bring about US$1.75 billion in annual sales. Do you think Merck will go on? Do you think now is a good time to buy the stock? Investors could check MRK earnings forecast report here.
Read Full Report: http://www.earningforecast.com/PR/031313A/MRK/Merck.pdf
Today EarningForecast.com also observed abnormal trade volume for the following companies; Check out the consensus earnings forecast reports below:
Apple Inc. (NASDAQ:AAPL):
Read Full Report: http://www.earningforecast.com/PR/031313A/AAPL/Apple.pdf
General Electric Company (NYSE:GE):
Read Full Report: http://www.earningforecast.com/PR/031313A/GE/GeneralElectric.pdf
America Movil SAB de CV (ADR) (NYSE:AMX):
Read Full Report: http://www.earningforecast.com/PR/031313A/AMX/AmericaMovilSABdeCV.pdf
EarningForecast.com focuses on tracking and monitoring company Earnings Data for top market movers in US stocks market. EarningForecast.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
Please visit: EarningForecast.com/disclaimers/index.php for details.